HUMA · Humacyte, Inc.

Summary

Humacyte, Inc. entered into securities purchase agreements on March 19, 2026, to issue and sell 25,000,000 shares of common stock at $0.80 per share in a registered direct offering, expecting gross proceeds of $20 million and net proceeds of approximately $18.4 million after fees and expenses. The proceeds will fund Symvess commercialization in vascular trauma, a hemodialysis BLA supplement, Phase 3 results readout, pipeline development, and general corporate purposes.

Key takeaways

• Entered Purchase Agreements for 25,000,000 shares at $0.80 per share, gross $20 million
• Net proceeds approximately $18,400,000 after placement agent fees
• Placement Agent: Titan Partners Group LLC (6% fee)
• Expected closing on or about March 20, 2026, subject to customary conditions
• Offering pursuant to S-3 registration (File No. 333-290231)
• Led by new life science dedicated investor and long-only mutual fund